1 |
Abbas E, Shaker O, Abd El Aziz G, et al (2012). Epidermal growth factor gene pol-ymorphism 61A/G in patients with chronic liver disease for early detection of hepa-tocellular carcinoma: a pilot study. Eur J Gastroenterol Hepatol, 24, 458-63.
|
2 |
Abu Dayyeh BK, Yang M, Fuchs BC, et al (2011). a functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology, 141, 141-9.
DOI
|
3 |
Blanc P, Etienne H, Daujat M, et al (1992). Mitotic responsiveness of cultured adult human hepatocytes to epidermal growth factor, transforming growth factor alpha, and human serum. Gastroenterology, 102, 1340-50.
|
4 |
Chen K, Wei Y, Yang H, et al (2011). Epidermal growth factor +61 G/A polymor-phism and the risk of hepatocellular carcinoma in a chinese population. Genet Test Mol Biomarkers, 15, 251-5.
DOI
|
5 |
Chuang SC, La Vecchia C, Boffetta P (2009). Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett, 286, 9-14.
DOI
|
6 |
Chung YH, Kim JA, Song BC, et al (2002). Expression oftransforming growth fac-tor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer, 89, 977-82.
|
7 |
DerSimonian R, Laird NM (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
DOI
|
8 |
El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and mo-lecular carcinogenesis. Gastroenterology, 132, 2557-76.
DOI
|
9 |
El-Serag HB (2011). Hepatocellular carcinoma. New Engl J Med, 365, 1118-27.
DOI
ScienceOn
|
10 |
Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a metaanalysis. Statistics Medicine, 21, 1539-58.
DOI
|
11 |
Jorissen RN, Walker F, Pouliot N, et al (2003). Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res, 284, 31-53.
DOI
|
12 |
Lanuti, M (2008). A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res, 14, 3216-22.
DOI
|
13 |
Li Y, Xie Q, Lu F, et al (2010). Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. Liver Int, 30, 112-8.
DOI
|
14 |
Nicholas MK, Lukas RV, Jafri NF, et al (2006). Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res, 12, 7261-70.
DOI
|
15 |
Llovet JM, Bruix J (2008). Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 48, 1312-27.
DOI
|
16 |
Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retro-spective studies of disease. J Natl Cancer Inst, 22, 719-48.
|
17 |
Natarajan A, Wagner B, Sibilia M (2007). The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci USA, 104, 17081-6.
|
18 |
Qi P, Chen YM, Gao CF, et al (2008). Relationship between polymorphism of epi-dermal growth factor 59UTR Variant G61A gene and hepatocellular carcinoma in pa-tients with chronic hepatitis B virus infection in China. Chin J Biologicals, 21, 1051-3.
|
19 |
Qi P, Wang H, Chen YM, et al (2009). No association of EGF 5'UTR variant A61G and hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. Pathology, 41, 555-60.
DOI
|
20 |
Shahbazi M, Pravica V, Nasreen N, et al (2002). Association between functional polymorphism in EGF gene and malignant melanoma. Lancet, 359, 397-401.
DOI
|
21 |
Shi HZ, Ren P, Lu QJ, et al (2012). Association between EGF, TGF- and TNF- gene polymorphisms and hepatocellular carcinoma. Asian Pac J Cancer Prev, 13, 6217-20.
DOI
|
22 |
Stoscheck CM, King LE Jr (1986). Role of epidermal growth factor in carcinogenesis. Cancer Res, 46, 1030-7.
|
23 |
Wu J, Zhang W, Xu A, et al (2013). Association of epidermal growth factor and epidermal growth factor receptor polymorphisms with the risk of hepatitis b vi-rus-related hepatocellular carcinoma in the population of north china. Genet Test Mol Biomarkers, 17, 595-600.
DOI
|
24 |
Suenaga M, Yamada S, Fujii T, et al (2013). afunctional polymorphism in the epi-dermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis cpatients. Onco Targets Ther, 6, 1805-12.
|
25 |
Tanabe KK, Lemoine A, Finkelstein DM, et al (2008). Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA, 299, 53-60.
|
26 |
Wang HX, Xie WM, Zhou GQ (2009). Epidermal growth factor gene polymorphism associated with susceptibility to hepatocellular carcinoma. Guangxi Medical Univer-sity. Master Dissertation.
|
27 |
Yamaguchi K, Carr BI, Nalesnik MA (1995). Epidermal growth factor-induced hepa-tocellular carcinoma: gene expression profiles in precursor lesions, early stage and sol-itary tumours. J Surg Oncol, 58, 240-5.
DOI
|
28 |
Yang Z, Wu Q, Shi Y, et al (2012). Epidermal growth factor 61A>G polymorphism is associated with risk of hepatocellular carcinoma: a meta-analysis. Genet Test Mol Biomarkers, 16, 1086-91.
DOI
|
29 |
Yuan JM, Fan Y, Ognjanovic S, et al (2013). Genetic polymorphisms of epidermal growth factor in relation to risk of hepatocellular carcinoma: two case-control studies. BMC Gastroenterol, 18, 13, 32.
DOI
|
30 |
Yue AM, Xie ZB, Guo SP, et al (2013). Implication of polymorphisms in DNA repair genes in prognosis of hepatocellular carcinoma. Asian Pac J Cancer Prev, 14, 355-8.
DOI
|
31 |
Zhong JH, You XM, Gong WF, et al (2012). Epidermal growth factor gene poly-morphism and risk of hepatocellular carcinoma: a meta-analysis. PLoS One, 7, 32159.
DOI
|
32 |
Zender L, Villanueva A, Tovar V, et al (2010). Cancer gene discovery in hepatocellu-lar carcinoma. J Hepatol, 52, 921-9.
|
33 |
Zintzaras E, Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genetic epidemiology, 28, 123-37.
DOI
|